O
1.49
0.05 (3.47%)
| Penutupan Terdahulu | 1.44 |
| Buka | 1.48 |
| Jumlah Dagangan | 11,310 |
| Purata Dagangan (3B) | 68,292 |
| Modal Pasaran | 78,194,496 |
| Harga / Buku (P/B) | 7.94 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Aug 2024 |
| EPS Cair (TTM) | -0.380 |
| Nisbah Semasa (MRQ) | 0.280 |
| Aliran Tunai Operasi (OCF TTM) | -2.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.09 M |
| Pulangan Atas Aset (ROA TTM) | -291.87% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | OKYO Pharma Limited | Bercampur | Bercampur |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -2.5 |
| Persekitaran Makro | 0.0 |
| AI Insight | NA |
| Purata | -0.28 |
|
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 34.41% |
| % Dimiliki oleh Institusi | 6.13% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Maven Securities Ltd | 30 Jun 2026 | 809,317 |
| Choreo, Llc | 30 Jun 2026 | 33,255 |
| Efg International Ag | 30 Jun 2026 | 923 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |